Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29126214 | 0.87 | GPR35 (0.51) | GPR35ALDH1A1TSHRTP53HPGD | |
| SCHEMBL9000088 | 0.86 | HTT (0.46) | ALDH1A1TSHRHPGDMAPK1SMN1; SMN2 | |
| SCHEMBL9655475 | 0.83 | ALDH1A1 (0.51) | GPR35ALDH1A1TSHRTP53HPGD | |
| SCHEMBL9655466 | 0.83 | ALDH1A1 (0.51) | GPR35ALDH1A1TSHRTP53HPGD | |
| SCHEMBL22578674 | 0.82 | TDP1 (0.61) | GPR35ALDH1A1TSHRGAATHRB | |
| SCHEMBL5690779 | 0.80 | HTT (0.60) | GPR35ALDH1A1TSHRGAATHRB | |
| SCHEMBL10775779 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TP53SMN1; SMN2GAATDP1 | |
| SCHEMBL27639709 | 0.80 | ERN1 (0.55) | ALDH1A1TSHRGAATTRCA2 | |
| SCHEMBL443353 | 0.77 | TDP1 (0.64) | GPR35ALDH1A1TSHRTP53HPGD | |
| SCHEMBL31375357 | 0.77 | TDP1 (0.64) | GPR35ALDH1A1TSHRTP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376712-A1 | PAPER-BASED ANALYTICAL DEVICE FOR POTENTIOMETRIC ENZYME DETECTION | ABD RABBOH HISHAM S M (SA) | 2025-12-11 | — | — | US | claimed |
| US-20240093166-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-03-21 | — | — | US | claimed |
| US-20240076634-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-03-07 | — | — | US | claimed |
| US-20240002819-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2024-01-04 | — | — | US | claimed |
| US-20230340552-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | GINKGO BIOWORKS, INC. | 2023-10-26 | — | — | US | claimed |
| US-11773382-B2 | Engineered aryl sulfate-dependent enzymes | OPTIMVIA, LLC (US) | 2023-10-03 | — | — | US | claimed |
| US-11767518-B2 | Engineered aryl sulfate-dependent enzymes | OPTIMVIA, LLC (US) | 2023-09-26 | — | — | US | claimed |
| US-11708593-B2 | Engineered aryl sulfate-dependent enzymes | OPTIMVIA, LLC (US) | 2023-07-25 | — | — | US | claimed |
| US-11708567-B2 | Engineered aryl sulfate-dependent enzymes | OPTIMVIA, LLC (US) | 2023-07-25 | — | — | US | claimed |
| US-20230151339-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2023-05-18 | — | — | US | claimed |
| US-20210363504-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | GINKGO BIOWORKS, INC. | 2021-11-25 | — | — | US | claimed |
| US-20210363503-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | OPTIMVIA LLC (US) | 2021-11-25 | — | — | US | claimed |
| EP-3911737-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | Optimvia, LLC (US) | 2021-11-24 | — | — | EP | claimed |
| CN-113646427-A | Engineered arylsulfate-dependent enzymes | 奥普蒂姆维亚有限公司 | 2021-11-12 | — | — | CN | claimed |
| WO-2021007429-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | OPTIMVIA LLC (US) | 2021-01-14 | — | — | WO | claimed |
| WO-2020150350-A1 | ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES | OPTIMVIA, LLC (US) | 2020-07-23 | — | — | WO | claimed |
| EP-2137204-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | Amicus Therapeutics, Inc. (US) | 2009-12-30 | — | — | EP | claimed |
| WO-2008128089-A1 | USE OF SUBSTRATES AS PHARMACOLOGICAL CHAPERONES | AMICUS THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | claimed |
| EP-0531537-B1 | HIRUDIN ANALOGUE OR SALT THEREOF, PRODUCTION THEREOF, AND ANTICOAGULANT CONTAINING THE SAME AS ACTIVE INGREDIENT | JAPAN ENERGY CORP (JP) | 1996-09-11 | — | — | EP | claimed |
| EP-0531537-A1 | HIRUDIN ANALOGUE OR SALT THEREOF, PRODUCTION THEREOF, AND ANTICOAGULANT CONTAINING THE SAME AS ACTIVE INGREDIENT | JAPAN ENERGY CORPORATION (JP) | 1993-03-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340552-A1 | METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES | CSGALNACT1, NANS, STS | GPR35 2881/4885ALDH1A1 1300/4885TSHR 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.